Abstract
Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.
Keywords: Angiogenesis, antihypertensive drugs, bevacizumab, endothelium, essential hypertension, vascular endothelial growth factor, vascular homeostasis, vasoconstriction, CVD
Current Vascular Pharmacology
Title:Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies
Volume: 10 Issue: 4
Author(s): Patrizia Ferroni, David Della-Morte, Raffaele Palmirotta, Tatjana Rundek, Fiorella Guadagni and Mario Roselli
Affiliation:
Keywords: Angiogenesis, antihypertensive drugs, bevacizumab, endothelium, essential hypertension, vascular endothelial growth factor, vascular homeostasis, vasoconstriction, CVD
Abstract: Essential hypertension may be a consequence of structural and functional alterations of the microvascular network growth resulting partly from abnormal regulation of vascular endothelial growth factor (VEGF), one of the most potent known angiogenic factors. As data from clinical trials on anti-VEGF drugs are becoming available, it is increasingly recognized that VEGF, in addition to being a proliferation and migration factor, is also a maintenance and protection factor for endothelial cells, whose altered regulation may cause a disturbance of vascular homeostasis. Elevated VEGF levels in hypertensive patients were shown to correlate with cardiovascular risk, early microvascular and target organ damage; accordingly treatment of hypertension significantly reduced VEGF levels. Recently and in agreement with the theory that impaired angiogenesis can contribute to increased peripheral resistance and raised blood pressure (BP), an involvement of VEGF gene promoter polymorphisms in the pathophysiology of hypertension has been hypothesized. In the last decade, anti-VEGF drugs have been used in clinical practice, especially in the oncology field. This review will summarize the present understanding of the contribution of VEGF to neoangiogenesis in hypertension and its possible role as a marker of vascular damage. Given the well established effects that antihypertensive drugs exert on the vasculature beyond BP lowering (pleiotropic effects), we will also discuss the effects of antihypertensive treatment on circulating VEGF levels. The biological mechanism and clinical impact of hypertensive complications during anti-angiogenic treatments will also be reviewed.
Export Options
About this article
Cite this article as:
Ferroni Patrizia, Della-Morte David, Palmirotta Raffaele, Rundek Tatjana, Guadagni Fiorella and Roselli Mario, Angiogenesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Therapies, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812836
DOI https://dx.doi.org/10.2174/157016112800812836 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Responses Triggered by the Immune System in Hypertensive Conditions and Repercussions on Target Organ Damage: A Review
Current Cardiology Reviews Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry The Coronary Collateral Circulation in Man
Current Cardiology Reviews Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer
Reviews on Recent Clinical Trials Applications of Fractal and Non-linear Time Series Analysis to the Study of Short-term Cardiovascular Control
Current Vascular Pharmacology Restoration of the Attenuated Neuroprotective Effect of Ischemic Postconditioning in Diabetic Mice by SGLT Inhibitor Phlorizin
Current Neurovascular Research Arterial Stiffness:A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Hypertension Reviews Prediction of Drug-Drug Interactions Arising From Mechanism-Based Inactivation: Key Input Parameters and Impact on Risk Assessment
Current Drug Metabolism Applications of Nucleic Acid Drugs for Organ Transplantation
Current Topics in Medicinal Chemistry Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Aspirin Hypersensitivity in Patients Undergoing Percutaneous Coronary Intervention. What Should We be Doing?
Current Vascular Pharmacology Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Recent Advance in Non-invasive Continuous Blood Pressure Measurement System
Recent Patents on Biomedical Engineering (Discontinued) Protein S-100B - A Prognostic Marker for Cerebral Damage
Current Medicinal Chemistry GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Serum Calprotectin as a Novel Biomarker in Abdominal Aortic Aneurysm Pathogenesis and Progression: Preliminary Data from Experimental Model in Rats
Current Vascular Pharmacology